Press release - 20/06/2023 CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study. CVGBM is based on CureVac’s proprietary second-generation mRNA backbone and features a single mRNA, encoding eight epitopes derived from known tumor-associated antigens with demonstrated relevance in glioblastoma. A first data readout is expected in the second half of 2024.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-patient-phase-1-study-cancer-vaccine-candidate-surgically-resected-glioblastoma
Press release - 03/09/2024 NMR Spectroscopy: A Faster Way to Determine the “Sense of Rotation” of Molecules Researchers of Karlsruhe Institute of Technology (KIT) and Voxalytic GmbH developed a new method that allows, for the first time, to elucidate the chiral structure of molecules – the exact spatial arrangement of the atoms – by nuclear magnetic resonance (NMR) spectroscopy. This important step in the development of new drugs used to be a time-consuming process until now. https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmr-spectroscopy-faster-way-determine-sense-rotation-molecules
Press release - 13/08/2024 Peptide Boronic Acids: New Prospects for Immunology A cutting-edge chemical process is the first to make it possible to quickly and easily produce modified peptides with boronic acids. As part of this work, scientists managed to synthesize a large number of different biologically active peptide boronic acids and investigate their properties. They open up new possibilities in the young research field of synthetic immunology and could go on to be used primarily in immunotherapy. https://www.gesundheitsindustrie-bw.de/en/article/press-release/peptide-boronic-acids-new-prospects-immunology
Press release - 16/05/2023 First company in the world to offer preclinical drug tests for children with cancer The recently established ITCC-P4 gGmbH provides academic institutions and pharmaceutical companies with a comprehensive repertoire of modern laboratory models of pediatric tumors. The aim is to systematically test new treatment options for children and adolescents with cancer and to contribute data to regulatory approval processes in order to make the development of new cancer therapies for children and adolescents more attractive.https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-company-world-offer-preclinical-drug-tests-children-cancer
Press release - 09/09/2024 New Molecular Engineering Technique allows for complex Organoids A new molecular engineering technique can precisely influence the development of organoids. Microbeads made of specifically folded DNA are used to release growth factors or other signal molecules inside the tissue structures. This gives rise to considerably more complex organoids that imitate the respective tissues much better and have a more realistic cell mix than before. https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-engineering-technique-allows-complex-organoids
Dossier - 11/10/2023 The quantum revolution in the healthcare industry From ultra-fast quantum computers to highly sensitive sensors - quantum technologies could take medicine a giant step forward. Possible areas of application range from drug development and early cancer detection to reading brain waves to control prostheses or exoskeletons. The German state of Baden-Württemberg plays a key role in the development of sensors in particular.https://www.gesundheitsindustrie-bw.de/en/article/dossier/The-quantum-revolution-in-the-healthcare-industry
Dossier - 23/07/2012 Extremophilic bacteria Extremophilic bacteria love it hot, sour or salty, toxic substances like heavy metals also do them good and even give them energy. As molecular and systems biology techniques get better and better, industry is also becoming increasingly interested in these exotic organisms. What potential does knowing the biochemistry of extremophilic bacteria have for the pharmaceutical, cosmetics and sanitary articles industries? https://www.gesundheitsindustrie-bw.de/en/article/dossier/extremophilic-bacteria
Press release - 06/02/2023 Fewer side effects thanks to personalised medicine Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.https://www.gesundheitsindustrie-bw.de/en/article/press-release/weniger-nebenwirkungen-dank-personalisierter-medizin
Press release - 14/03/2024 Next milestone in the treatment of liver tumors and acute and chronic liver diseases The results of a Tuebingen-led study raise hope that a newly developed drug could herald a new era in oncological liver surgery and transplantation. The drug could even have the potential to significantly improve the treatment of acute and chronic liver diseases. The drug candidate "HRX-215" is a so-called MKK4 inhibitor, i.e. the drug inhibits the MKK4 protein found in liver cells and thus leads to an increase in the regeneration of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/next-milestone-treatment-liver-tumors-and-acute-and-chronic-liver-diseases
BIOPRO Baden-Württemberg publishes first results of a new WifOR study - 11/09/2024 Industrial healthcare industry in Baden-Württemberg: gross value added of more than 19 billion euros The industrial healthcare sector (iGW) plays a central role in the economy in Baden-Württemberg. In 2021, the sector generated a direct gross value added of 19.6 billion euros, which corresponds to around a third (32.6%) of the entire regional healthcare industry. Of 96.3%, almost all of the healthcare sectors's exports in the state in 2021 came from the iGW. These are the findings of a new study conducted on behalf of BIOPRO…https://www.gesundheitsindustrie-bw.de/en/article/press-release/industrial-healthcare-industry-baden-wuerttemberg-gross-value-added-more-19-billion-euros
Press release - 23/01/2025 ERC Funding for „EmbryoNet-AI“ Konstanz biologist Patrick Müller receives a Proof of Concept Grant from the European Research Council for his project "EmbryoNet-AI". Its goal is the further development of an AI-supported platform for the automated evaluation of experiments – for example, in drug development.https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-funding-embryonet-ai